Merck的新药显示,在降低“坏”胆固醇而不产生显著副作用方面,取得了有希望的成果。 Merck's new drug shows promising results in lowering "bad" cholesterol without significant side effects.

Merck & Co.宣布其实验性胆固醇低落药物(enculited Decanoate)的第三阶段试验成功结果,显示高胆固醇患者的“坏”胆固醇(LDL-C)水平显著下降,没有显著副作用。 Merck & Co. announced successful Phase 3 trial results for its experimental cholesterol-lowering drug, enlicitide decanoate, showing significant reductions in "bad" cholesterol (LDL-C) levels in patients with high cholesterol, without notable side effects. 该药物的表现优于安慰剂和其他口服非统计疗法。 The drug performed better than placebos and other oral non-statin therapies. 如果获得批准,这可能是美国第一个口服PCSK9抑制剂,有可能促进Merck的销售。 If approved, it could be the first oral PCSK9 inhibitor in the U.S., potentially boosting Merck's sales.